TM7SF2 and cancer: These findings establish TM7SF2-mediated cholesterol metabolism as a druggable axis in chemoresistance, aligning with emerging evidence that cholesterol-rich lipid rafts facilitate survival signaling and drug efflux in resistant cancers.